February 20, 2026
Poland entered 2025 with two compliance realities that look contradictory at first glance:
For operators, the practical result is a market where topical and cosmetic formats tend to be lower-risk than gummies, beverages, tinctures marketed as supplements, or other ingestibles—especially if you are importing into Poland or selling online cross‑border.
This article (1) explains the enforcement trend driving Poland CBD regulations 2025, (2) provides a compliance checklist for CBD food/supplement importers and online sellers, and (3) summarizes how Poland’s late‑2024 prescribing/telemedicine restrictions reshaped medical access pathways.
Not legal advice. This is an informational overview for compliance planning.
Across the EU, “Novel Foods” are governed by Regulation (EU) 2015/2283. If a food or ingredient was not consumed to a significant degree in the EU before 15 May 1997, it generally requires pre‑market authorization and placement on the Union list.
The European Commission maintains a non-binding but influential Novel Food status catalogue. Its current logic is straightforward:
Official resources:
Poland’s enforcement climate cannot be separated from EFSA’s work on CBD safety. EFSA publicly stated it could not finalize safety conclusions due to data gaps, and later published updates including a provisional safe intake level while still highlighting major uncertainties.
Key EFSA references:
For businesses, the takeaway is operational rather than academic: Member State food authorities have stronger justification to intervene when CBD ingestibles are marketed without a clear authorization pathway.
Poland distinguishes “fibrous hemp” and “non‑fibrous” categories using a 0.3% THC threshold referenced in multiple legal and industry practice guides. Meanwhile, on the EU agriculture side, the EU has moved to a 0.3% THC cap for hemp eligibility under CAP rules (field controls and payments), and EU food contaminant limits for THC in hemp seed foods have also tightened via EU legislation.
Helpful EU reference on hemp and EU controls:
However, note the nuance: meeting a THC limit does not resolve Novel Food status. Many operators fail compliance because they focus on THC COAs but ignore authorisation and food-law classification.
A practical way to see enforcement direction is the EU’s Rapid Alert System for Food and Feed (RASFF). In 2024–2025, there were RASFF entries involving products from Poland containing cannabinoids characterized as unauthorized novel food ingredients, with measures such as withdrawals and sales bans.
Examples:
Compliance implication: if you sell ingestible CBD online in or from Poland, assume that digital storefronts are visible to authorities across borders and may become the basis for follow‑up actions.
Importers (especially from outside the EU/EEA) face compounding friction:
The central point for Poland CBD regulations 2025 is not “whether CBD is legal” in the abstract, but whether your specific SKU is lawful in its format, claims, and documentation.
This checklist is written for brands, importers, distributors, and online sellers handling tinctures, capsules, gummies, beverages, powders, or any ingestible format.
Start by documenting the ingredient source:
If it is an extract/isolate, you need an authorization pathway under the EU Novel Food regime—or you must reassess market strategy.
Action:</strong write an internal “Novel Food position memo” per SKU, including botanical part, extraction method, and whether there is credible evidence of pre‑1997 consumption (often difficult for cannabinoid-rich extracts).
Misclassification is a major enforcement trigger.
Action:</strong align product format + claims + channel. Do not reuse the same marketing copy for cosmetics and ingestibles.
Even when a product is otherwise lawful as a food/supplement, EU rules prohibit unauthorised health claims.
Key legal framework:
What to watch for (high risk):</strong claims about anxiety, pain, inflammation, sleep disorders, depression, ADHD, epilepsy, or “supports the immune system” without an authorised claim for that ingredient in that context.
Action:</strong implement a marketing-claims review process (label + website + social + influencer scripts). In enforcement practice, the website often becomes “the label.”
Food information rules in the EU are anchored in Regulation (EU) 1169/2011 (Food Information to Consumers). Poland also requires that food marketed in Poland be labeled in Polish.
A practical summary of the Polish language requirement is frequently referenced in compliance guides, and is also reflected in import guidance materials.
Reference examples:
Action:</strong ensure that:
Poland uses a notification-based system for supplements overseen by the Chief Sanitary Inspectorate (GIS). The compliance risk here is not only whether you notified, but whether your product is later “questioned” as non‑compliant.
While many operational guides are secondary sources, they consistently describe that supplement notification is expected prior to marketing.
Action:</strong keep a complete dossier ready to provide quickly if the product is challenged, including:
For importers and wholesalers, documentation discipline is often the difference between a routine shipment and a stop.
Minimum recommended pack (per batch/SKU):
Action:</strong include a “regulatory narrative” one‑pager that states what the product is (and is not), and which legal framework you believe applies.
Online sellers should treat Poland as a jurisdiction with active consumer‑protection enforcement, especially around misleading advertising and influencer marketing disclosures.
Example UOKiK (Office of Competition and Consumer Protection) topic page for influencer marketing enforcement actions: https://uokik.gov.pl/en/tag/influencer-marketing
Action:</strong make sure influencer posts are properly disclosed as advertising and that product benefit claims do not drift into medicinal territory.
The RASFF entries linked above show that withdrawals and sales bans are realistic outcomes.
Action:</strong pre‑draft:
Poland has allowed medical access since 2017 via pharmacy dispensing on prescription, largely reliant on imported raw material and preparations. What changed sharply was the telemedicine pathway that had enabled scale.
In late 2024, Poland introduced changes that, in effect, required an in-person examination for prescribing certain controlled medicines, with limited exceptions (including narrow circumstances for primary care continuation). These changes became widely discussed because they hit high‑volume telemedicine clinics.
Official reference (Patient Ombudsman explanation of the rule change, noting the change effective 7 November 2024 and in‑person examination requirement for certain medicines, including medical cannabis): https://www.gov.pl/web/rpp/zmiany-w-wypisywaniu-recept--jak-dziala-obowiazujacy-od-listopada-przepis
Underlying legal text reference (Poland’s legal acts system PDF for the amending regulation): https://eli.gov.pl/api/acts/DU/2024/1600/text/O/D20241600.pdf
Compliance takeaway for clinics and prescribers:</strong remote-first models became harder to operate at scale when initiation and/or certain prescribing events require physical examination.
Trade coverage and market analysis observed a steep decline in prescription volume following the restriction, with access increasingly concentrated in larger cities.
Even if you view the prescription trend data as secondary, the direction is consistent with the legal change: telehealth as the default access channel is no longer reliable.
Patients:
Pharmacies:
Clinics and prescribing entities:
Poland’s 2025 environment rewards operators who treat compliance as a product feature: documented supply chains, conservative claims, Polish‑language labeling discipline, and a realistic view of Novel Food risk for ingestibles. At the same time, medical access dynamics have shifted as telehealth pathways narrowed—changing demand patterns and patient journeys.
If you’re launching, importing, or scaling in Poland, use CannabisRegulations.ai to stress‑test product classification, claims, labeling, and documentation against fast‑moving enforcement trends: https://www.cannabisregulations.ai/
